glp 1 research Another milestone in the evolution of GLP-1-based diabetes therapies GLP-1 Agonists Weight Loss Drugs
Description
From July 1, 2026, Medicare will cover Wegovy and Zepbound for weight loss through a temporary federal program called the Medicare GLP-1 bridge: with a new model coming into place in 2027
They are now part of a broader medical discussion about obesity, insulin resistance, cardiovascular risk, fatty liver disease, inflammation, body composition, appetite signaling, and long-term metabolic health
Author contributions Conceptualization: SS, AM
Nevertheless, no significant difference was detected regarding metabolic indices, such as Diastolic BP, systolic BP, TC, and TG
Abstract Purpose of Review
[DOI] [PubMed] [Google Scholar] 58.Zhu CG, Luo Y, Wang H, Li JY, Yang J, Liu YX, et al
